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Background: The renal distal nephron plays an important role in the maintenance of sodium balance, extra cellular
volume and blood pressure. The degree of water transport, via aquaporin2 water channels (AQP2), and sodium
transport, via epithelial sodium channels (ENaC) in renal collecting duct principal cells are reflected by the level of
urinary excretion of AQP2 (u-AQP2) and the γ-fraction of ENaC (u-ENaCγ). The effects of an acute intravenous
volume load with isotonic saline, hypertonic saline and glucose on u-AQP2, u-ENaCγ and underlying mechanisms
have never been studied in a randomized, placebo-controlled trial in healthy humans.
Methods: We studied the effects of 0.9% saline (23 ml/kg), 3% saline (7 ml/kg) and 5% glucose (23 ml/kg) on
u-AQP2 and u-ENaCγ, fractional sodium excretion (FENa), free water clearance (CH2O), and plasma concentrations of
vasopressin (AVP), renin (PRC), angiotensin II (ANG II) and aldosterone (Aldo) in a randomized, crossover study of 23
healthy subjects, who consumed a standardized diet, regarding calories, sodium and fluid for 4 days before each
examination day.
Results: After isotonic saline infusion, u-AQP2 increased (27%). CH2O and u-ENaCγ were unchanged, whereas FENa
increased (123%). After hypertonic saline infusion, there was an increase in u-AQP2 (25%), u-ENaCγ (19%) and FENa
(96%), whereas CH2O decreased (−153%). After isotonic glucose infusion, there was a decrease in u-AQP2 (−16%),
ENaCγ (−10%) and FENa (−44%) whereas CH2O increased (164%). AVP remained unchanged after isotonic saline and
glucose, but increased after hypertonic saline (139%). PRC, AngII and p-Aldo decreased after isotonic and
hypertonic saline infusion, but not after glucose infusion.
Conclusions: Volume expansion with 3% and 0.9% saline increased u-AQP2, while isotonic glucose decreased u-
AQP2. Infusion of hypertonic saline increased u-ENaCγ, whereas u-ENaCγ was not significantly changed after
isotonic saline and tended to decrease after glucose. Thus, the transport of water and sodium is changed both via
the aquaporin 2 water channels and the epithelial sodium channels during all three types of volume expansion to
regulate and maintain water- and sodium homeostasis in the body.
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The distal nephron plays an important role in the main-
tenance of sodium balance, extra cellular fluid volume and
blood pressure [1]. It is well known that inappropriate
water and sodium retention is thought to be a key factor
in several forms of hypertension, and that aquaporin2
waterchannels (AQP2) play a key role in several water bal-
ance disorders [2,3]. Animal models have shown a reduced
AQP2 expression in conditions with acquired nephrogenic
diabetes insipidus such as lithium treatment and an in-
creased expression in diseases with water retention such
as congestive heart failure [4]. Gain-of-function mutations
in the epithelial sodium channels (ENaC) cause inappro-
priate renal sodium retention and consequent increases
blood pressure [5]. Because AQP2 and ENaC plays such
an important role in water and sodium balance and associ-
ated disorders, it is important to identify factors involved
in the reabsorption of water and sodium by the kidneys in
order to study these disorders in the future.
The exact role of AQP2 and ENaC has never been ex-
amined under volume expansion in healthy humans. The
effect of an acute intravenous volume load, with isotonic
and hypertonic saline and glucose, on urinary excretion
of AQP2 (u-AQP2), urinary excretion of ENaC gamma
subunit fractions (u-ENaCγ) and its relationship to vaso-
pressin (AVP) and kidney function in healthy humans has
not been studied by simultaneous measurement of other
important regulatory hormones of water and sodium
homeostasis such as the renin-angiotensin-aldosterone
system (RAAS).
In this present study we wanted to study the sodium
and water transport in the distal nephron by measuring
1) the excretion of u-AQP2 and u-ENaCγ 2) associated
regulating hormones and 3) the renal response after
volume expansion in healthy humans.
In order to analyse these physiological mechanisms,
we performed a randomized, crossover study in healthy
subjects. We investigated the effects of infusion with
isotonic- and hypertonic saline and isotonic glucose on
urinary excretion of AQP2 and ENaCγ corrected for
creatinine (u-AQP2CR and u-ENaCγCR), renal function





Healthy non-smoking men and women with age between
18 – 45 years were included in this study.
Exclusion criteria
Subjects with clinical signs or history of heart, lung,
kidney, endocrine or malignant disease; abnormal find-
ings in ECG, urine dipstick or biochemistry (blood cellcount, plasma concentrations of haemoglobin, sodium,
potassium, creatinine, albumin, glucose, bilirubin, alanine
aminotransferase, alkaline phosphatase and cholesterol);
arterial hypertension (ambulatory BP >130/80 mmHg);
medical treatment; alcohol and substance abuse; present
smoking; pregnancy; breast feeding; donation of blood
within one month prior to the study and obesity
(BMI > 32 kg/m2) were excluded from this study.
Withdrawal criteria
Subjects who developed the condition given in exclu-
sion criteria during the course of the experiment, who
withdrew their informed consent, and who had a poor
compliance were withdrawn from this study.
Ethics
This study was approved by the Regional Committee on
Health Research Ethics (j. no. M-2011003) and carried
out in accordance with the Helsinki Declaration. Written
informed consent was obtained from all subjects.
Recruitment
Healthy male and female volunteers were recruited through
advertisement at public institutions in Holstebro, Denmark.
Design
The study was conducted as a randomized, placebo-
controlled, crossover study. On three different occasions
separated by at least two weeks, subjects were randomised
to 0.9% isotonic saline (0.9% NaCl), 3.0% hypertonic saline
(3% NaCl) or 5% glucose (glucose), which was adminis-
tered as a sustained infusion over 60 minutes.
The amount of fluid used in this study was 0.9% NaCl:
23 ml/kg, 3% NaCl: 7 ml/kg and glucose: 23 ml/kg.
Effect variables
The main effect variables were u-AQP2, as well as
u-ENaCγ. Other effect variables were diastolic (DBP) and
systolic blood pressure (SBP), plasma concentration of
renin (PRC), angiotensin II (AngII), aldosterone (Aldo),
vasopressin (AVP), free water clearance (CH2O), glomeru-
lar filtration rate (GFR), fractional excretion of sodium
(FENa) and potassium (FEK), plasma sodium (p-Na), urine
osmolality (u-osm), plasma osmolality (p-osm) and plasma
albumin (p-alb).
Number of subjects
Using a significance level of 5% and a power of 90% it
was calculated that the number of subjects needed were
21, when the minimal relevant difference in U-ENaCγ
was 100 ng./min and SD was 95 ng./min. Incomplete
voiding during examination days was expected in some
subjects, therefore 26 subjects were included in the
study.
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Experimental procedure prior to the study day
Four days prior to each study day, subjects consumed a
standardized diet regarding calories, sodium and fluid.
The diet consisted of 11,000 kJ/day with an energy dis-
tribution of 55% carbohydrates, 30% fat and 15% protein
in accordance to general dietary guidelines. The sodium
content was 120 mmol pr. day. The subjects were asked
to drink exactly 2500 ml/day. No alcohol, coffee, tea or
soft drink consumption was allowed while on the stan-
dardized diet. Subjects were instructed to keep their
physical activity as usual during the experiments and to
abstain from hard training.
A 24-hour urine collection, ending at 7:00 AM on the
examination-day, was used to assess water and sodium
balance.Experimental procedure on the study day
After an overnight fast, subjects arrived at our facility at
8:00 AM. Two indwelling catheters for blood sampling
and administration of 51Cr –EDTA and fluid were placed
in both cubital veins. Every 30 minutes, starting at arrival,
participants received a 175 ml oral water load of tap water.
Urine was collected in standing or sitting position. Other-
wise subjects were kept in supine position in a quiet
temperature-controlled room (22-25°C).
Three 30 minutes baseline clearance periods were
obtained from 9:30 AM to 11:00 AM. These were followed
by one clearance period from 11:00 AM to 12:00 PM dur-
ing which a sustained infusion of either glucose, 0.9%
NaCl or 3% NaCl was administered. The post infusion
period consisted of three 30-minute periods from
12:00 PM to 1:30 PM. Blood and urine samples were
collected every 30 minutes from 9:30 AM to 1:30 PM and
analysed for 51Cr-EDTA, electrolytes and osmolality.
Analysis of plasma concentrations of PRC, Ang II, Aldo
and AVP were conducted from blood samples drawn at
11:00 AM (baseline), 12:00 AM (cessation of fluid infusion),
12:30 PM (30 min after cessation of fluid) and 1:30 PM
(90 min after cessation of fluid). For data analysis, the
30-minute periods were subdivided into: baseline (0–
90 min), infusion (90–150 min) and post infusion (150–
180 min, 180–210 min, 210–240 min).Measurements
Renal function
Glomerular filtration rate was measured by the constant
infusion clearance technique using 51Cr-EDTA as refer-
ence substance. A priming dose of 51Cr-EDTA was given
followed by sustained infusion that was kept stable using a
volume-controlled infusion pump. More than 15% vari-
ation in GFR between the three baseline periods led to
exclusion of analysis.Blood samples
Were centrifuged for 10 minutes at 2200 × g at 4°C.
Plasma hormone samples were kept frozen at −20°C
(AngII) and −80°C (PRC, Aldo, and AVP) until assayed.
Renin in plasma was determined using an im-
munoradiometric assay from and a kit from CIS Bio
International, Gif-Sur-Yvette Cedex, France. Minimal
detection level was 1 pg./mL the coefficients of variation
were 14.5% (interassay) and 4.5% (intra assay). Aldoster-
one in plasma was determined by radioimmunoassay
using a kit from Demeditec Diagnostics Systems Labora-
tories Inc. (Webster, TX, USA). Minimal detection level
was 22 pmol/L. The coefficients of variation were 8.2%
(inter-assay) and 3.9% (intra-assay). Arginine vasopressin
and Angiotensin II were extracted from plasma with C18
Sep-Pak (water associates, Milford, MA, USA) and subse-
quently measured using radioimmunoassay as previously
described. The antibody against angiotensin II was
obtained from the Department of Clinical Physiology,
Glostrup Hospital, Glostrup, Denmark. Minimal detection
level was 2 pmol/L. The coefficients of variation were 12%
(inter-assay) and 8% (intra-assay). The antibody against
AVP was a gift from Professor Jacques Dürr (Miami, FL,
USA). Minimal detection level was 0.2 pmol/L. The
coefficients of variation were 13% (inter-assay) and 9%
(intra –assay).Urine samples
Were kept frozen at −20°C until assayed. U-AQP2 was
measured by radioimmunoassay as previously described
[6,7]. Antibodies were raised in rabbits to a synthetic pep-
tide corresponding to the 15 COOH-terminal amino acids
in human AQP2 to which was added an NH2-terminal
cystein for conjugation and affinity purification. Minimal
detection level was 34 pg/tube/tube. The coefficients of
variation were 11.7% (inter-assay) and 5.9% (intra-assay).
U-ENaCγ was measured by radioimmunoassay as previ-
ously described [8,9]. Antibodies were raised against the
synthetic ENaCγ peptide in rabbits and affinity purified as
described previously [10]. Minimal detection level was
48 pg/tube. The coefficients of variation were 14% (inter-
assay) and 6.7% (intra-assay).Blood pressure measurement
Brachial blood pressure was recorded using a semiautomatic
oscillometric devise (Omron 705IT, Omron Matsusaka,
Japan).
Plasma and urine concentrations of sodium, potassium,
creatinine and albumin were measured using routine
methods at the Department of Clinical Biochemistry,
Holstebro Hospital.
Fractional excretion of sodium was calculated as [sodium
clearance (CNa)/GFR × 100%].
Jensen et al. BMC Nephrology 2013, 14:202 Page 4 of 14
http://www.biomedcentral.com/1471-2369/14/202Fractional excretion of potassium was calculated as
[potassium clearance (CK)/GFR × 100%].
Free water clearance was calculated as [urine output
(UO) – osmolar clearance (COMS)].
COSM was calculated as [urine osmolarity/plasma
osmolarity × UO].
Statistics
Statistical analyses were performed using IBM SPSS statis-
tics version 20.0.0 (IBM Corp.; Armonk, NY, USA). Single
baseline values were obtained by taking the weighed aver-
age of the measurements from the three baseline periods.
Parametric data are presented as means ± standard devi-
ation (SD) and nonparametric data as medians with inter-
quartile ranges. General linear model (GLM) with
repeated measures was performed, with time as within-
subject factor and intervention as between subject factor,
to test for differences within and between groups. One-
way ANOVA was used for comparison of means between
groups when differences were found. For non-parametric
data related samples Friedman’s two-way analysis (FM)
was used. For comparison within groups at baseline and
post infusion period 210–240 minutes, a paired t-test was
used when data were parametric and Wilcoxon’s signed
rank test was used when data were nonparametric. Statis-
tical significance was defined as p < 0.05 in all analyses.
Results
Demographics
A total of 31 healthy women and men were enrolled in
the study. Five subjects were excluded due to: abnormal
blood samples (1), 24-h BP above 130/80 mmHg (1), non-
compliance (1) and withdrawal of informed consent (2).
Thus, 26 persons completed the study. Three were not
able to void satisfactorily during clearance experiments
and were excluded from analysis. One was not able to void
in two post intervention periods after 3% NaCl and was
excluded in channel analysis only.Table 1 Urine output, urine osmolarity (u-osm), free water cle
(u-AQP2), urinary excretion of ENaCγ per minute (u-ENaCγ), u
sodium (FENa) during 24-hours urine collection with fluid dep
study of 23 healthy subjects
Exa
0.9% NaCl
Urine Output (ml/24 h) 2306(559)




u-Na (mmol/24 h) 124(52)
FENa (%) 0.49(0.15)
Values are means with SD in brackets. One-way ANOVA was used for comparison bThe remaining 23 males (n = 9) and women (n = 14)
had a median age of 26 years (range 18–42) and a mean
BMI of 24.4 ± 2.3 kg/m2. Mean ambulatory blood pressure
was 119/70 ± 8/4 mmHg. Screening blood values were
b-haemoglobin 8.5 ± 0.7 mmol/L, p-sodium 139 ± 2,
p-potassium 3.9 ± 0.4 mmol/L, p-creatinine 74 ± 9 μmol/L,
p-albumin 42 ± 3 g/L, p-glucose 5.1 ± 0.6 mmol/L, p-
alanine transaminase 25 ± 9 U/L and p-cholesterol 4.5 ±
0.5 mmol/L.
Twenty-four-hour urine collection
Table 1 shows the results of the 24-h urine collection in
23 healthy subjects after 4 days of standardized diet.
Mean u-AQP2, u-ENaCγ, urinary sodium, urine osmo-
larity, CH2O and urine volume were the same in all three
examination days indicating that the subjects had kept
their supplied diets and fluid intake.
Water excretion, u-AQP2, u-osm
Table 2 shows the absolute values of UO, CH2O, u-AQP2CR,
u-AQP2 excretion rate and u-osm during the baseline
period, the infusion period and the post infusion period.
UO increased significantly after 0.9% NaCl and glucose.
The 3% NaCl infusion induced a significantly and sustained
decrease in UO. The relative changes in UO were signifi-
cantly different between the three interventions.
CH2O increased during the infusion with 0.9% NaCl, and
decreased slightly, although significant in the postinfusion
period. At the end of the examination-day CH2O increased
towards baseline levels with an over all relative change
of −10%. There was a pronounced increase in CH2O after
glucose, whereas CH2O decreased after 3% NaCl and
changed from positive values at baseline to negative values
after infusion. Thus, indicating a change from free water
excretion to water reabsorption (Table 2).
U-AQP2CR increased by 27% (p < 0.001) in response to
0.9% and by 26% (p < 0.0001) after 3% NaCl and reached
maximum at 240 min after baseline. During glucosearance (CH2O), urinary AQP2 excretion per minute
rinary sodium excretion (u-Na) and fractional excretion of











Table 2 Effect of 0.9% isotonic saline (0.9% NaCl), 3% hypertonic saline (3% NaCl) and isotonic glucose (Glucose) on
urinary output (OU), free water clearence (CH2O), urine osmolarity (u-osm), urinary aquaporin2 excretion rate (u-AQP2)
and urinary aquaporin2 corrected for creatinine (u-AQP2CR) in a randomized, crossover study of 23 healthy subjects
Periods Baseline Infusion Post infusion p (GLM-within)
0-90 min 90-150 min 150-180 min 180-210 min 210-240 min
UO (ml/min)
0.9% NaCl 6.90(1.33) 8.75(1.76) 7.95(2.31) 7.39(2.36) 8.12(2.26)
<0.00013% NaCl 7.12(1.35) 2.75(0.73) 1.81(0.64) 1.98(1.07) 2.05(1.09)**
Glucose 6.83(1.58) 11.84(2.28) 16.05(2.82) 15.28(2.47) 13.45(2.47)**
p (GLM between) <0.0001
p ANOVA 0.77 <0.0001 <0.0001 <0.0001 <0.0001
CH2O
0.9% NaCl 3.87(1.55) 5.29(1.44) 4.07(2.09) 3.01(2.04) 3.62(1.59)
<0.00013% NaCl 3.97(1.21) −0.35(0.73) −1.87(0.83) −2.22(0.88) −2.26(0.96)
Glucose 3.84(1.32) 6.38(1.77) 11.60(0.52) 12.47(2.35) 11.17(2.12)
p (GLM between) <0.0001
p ANOVA 0.95 <0.0001 <0.0001 <0.0001 <0.0001
U- osm (mosmol/kg)
0.9% NaCl 140(62) 115(21) 149(58) 176(50) 161(33)
<0.00013% NaCl 136(37) 342(96) 606(114) 637(105) 640(111)*
Glucose 136(41) 133(21) 79(21) 52(12) 48(7)*
p (GLM between) p <0.0001
p ANOVA 0.95 <0.0001 <0.0001 <0.0001 <0.0001
u-AQP2 (ng/min)
0.9% NaCl 1.03 (0.25) 1.02(0.22) 1.22(0.34) - 1.26(0.32)*
<0.00013% NaCl 1.02(0.22) 0.99(0.31) 1.28(0.30) - 1.37(0.34)*
Glucose 1.01(0.22) 1.26(0.25) 1.19(0.29) - 0.78(0.18)*
p (GLM between) 0.274
u-AQP2CR (ng/mmol)
0.9% NaCl 102.5(19.9) 110.8(18.1) 119.8(25.4) - 125.0(21.0)**
<0.00013% NaCl 105.9(15.7) 108.6(27.2) 125.1(31.4) - 132.7(26.5)*
Glucose 105.7(19.1) 137.1(22.3) 118.1(26.5) - 87.9(15.4)*
p (GLM between) 0.565
Values are mean with SD in brackets. General linear model (GLM) with repeated measures was performed for comparison within the group and intervention as
between subjects factor. One way ANOVA was performed when differences were found between interventions. Paired t-test was used for comparison within
treatment group at baseline and post infusion period 210 – 240 minutes. *p < 0.0001; **p < 0.001.
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http://www.biomedcentral.com/1471-2369/14/202infusion (90–150 min) there was a primary increase in
u-AQP2CR after which u-AQP2CR decreased and reached
a minimum of - 16% (p < 0.0001) at 210–240 min
(Figure 1A). The excretion of u-AQP2 divided by
gender, showed that u-AQP2CR tended to be higher
in women than in men, but there was no statistical
significant difference. This was due to a lower cre-
atinine concentration in women’s urine (data not shown).
U-AQP2 excretion rate followed the same pattern
(Table 2). The relative changes in u-AQP2 did not differ
between 3% NaCl and 0.9% NaCl, but both weresignificantly different from the relative change in u-AQP2
after glucose infusion.
U-Osm decreased during 0.9% NaCl infusion with
minimum after infusion ended at 150 minutes, after
which u-osm increased, coherent with the changes seen
in CH2O. U-osm increased significantly in response to
3% NaCl and lasted throughout the experiment. During
glucose infusion u-osm remained constant for 60 mi-
nutes until glucose infusion was completed, after which




















































































































Figure 1 Effects of isotonic 0.9% saline (■), hypertonic 3% saline (♦) and isotonic glucose (●) on urinary excretion of A) u-AQP2 and
B) u-ENaCγ adjusted to creatinine, C) plasma concentration of vasopressin (AVP) and D) plasma osmolality in 23 healthy subjects.
Values are means ± SEM. Paired t-test was used for comparison of post infusion period 210–240 min vs. baseline. * p < 0.01; ** p < 0.001;
*** p < 0.0001.
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Table 3 shows the absolute values of u-Na, FENa, u-K,
FEK, u-ENaCγCR and u-ENaCγ excretion rate during the
baseline period, the infusion period and the post infu-
sion period.
Infusion with 0.9% NaCl and 3% NaCl were accom-
panied by a significant and similar increase in u-Na and
FENa that lasted throughout the experiment. There were
no significant differences between 0.9% NaCl and 3%
NaCl infusions. In contrast, U-Na and FENa decreased
after glucose infusion. The relative changes in u-Na and
FENa were significant lower after glucose compared to
both saline infusions.
U-K and FEK decreased significantly after all three
infusions, but with the greatest extend after glucose in-
fusion. In the post infusion period (150–240 min) the
excretion of potassium in urine increased slightly more
after 3.0% NaCl than 0.9% NaCl, but did not reach base-
line levels.U-ENaCγCR decreased slightly, but non-significantly
during 0.9% NaCl and glucose infusions. A significant
increase was seen in u-ENaCγCR in response to 3%
NaCl (p < 0.01) (Figure 1B) and the relative increase in
u-ENaCγCR were significantly higher in response to 3%
NaCl compared to 0.9% NaCl and glucose. Divided by
gender the differences in u-ENaCγCR showed no statistical
significant difference, although u-ENaCγCR tended to be
higher in women due to the lower urine creatinine (data
not shown). U-ENaCγ excretion rate followed the same
pattern with regard to saline infusions, whereas a signifi-
cantly lower u-ENaCγ excretion rate occurred after glu-
cose infusion (Table 3).
Vasoactive hormones
PRC, Ang II and Aldo were suppressed to the same extent
in all three parameters in response to 0.9% NaCl and 3%
NaCl with no significant difference between interventions.
There was a primary decrease during glucose infusion
Table 3 Effect of 0.9% isotonic saline (0.9% NaCl), 3% hypertonic saline (3% NaCl) and isotonic glucose (Glucose) on
urinary sodium excretion (u-Na), fractional excretion of sodium (FENa), urinary potassium wxcretion (u-K), fractional
excretion of potassium (FEK), urinary gamma fraction of the epithelial sodium channels excretion rate (u-ENaCγ) and
urinary gamma fraction of ENaC corrected for creatinine (u-ENaCγCR)
Periods Baseline Infusion Post infusion p (GLM
within)0-90 min 90-150 min 150-180 min 180-210 min 210-240 min
u-Na (mmol/min)
0.9% NaCl 1.24(0.55) 1.83(0.56) 2.51(1.05) 2.78(0.99) 3.07(0.98)*
<0.00013% NaCl 1.38(0.58) 1.86(0.75) 2.65(1.06) 2.94(1.44) 3.17(1.38)*
Glucose 1.23(0.51) 1.38(7.3) 0.94(0.43) 0.83(0.35) 0.72(0.35)*
p (GLM between) <0.0001
p (ANOVA) 0.599 0.028 <0.0001 <0.0001 <0.001
FENa
0.9% NaCl 1.26(0.53) 1.93(0.61) 2.35(0.72) 2.67(0.76) 2.80(0.75)*
<0.00013% NaCl 1.44(0.61) 2.08(0.81) 2.66(1.07) 3.07(1.27) 3.01(1.26)*
Glucose 1.27(0.53) 1.36(0.64) 0.88(0.37) 0.81(0.37) 0.74(0.37)*
p (GLM between) <0.0001
p (ANOVA) 0.465 0.002 <0.0001 <0.0001 <0.0001
U-K (mmol/min)
0.9% NaCl 26.5(9.1) 22.5(7.6) 21.1(8.9) 22.7(12.2) 23.5(10.2)***
<0.00013% NaCl 25.4(9.2) 17.3(7.3) 16.9(8.1) 20.1(10.5) 21.1(9.9)***
Glucose 24.9(8.7) 17.2(5.8) 10.8(3.7) 9.6(3.2) 11.23(4.4)*
p (GLM between) <0.0001
p (ANOVA) 0.827 0.016 <0.0001 <0.0001 <0.0001
FEK
0.9% NaCl 28.2(9.9) 23.3(7.4) 20.4(7.8) 21.5(8.2) 21.5(7.9)***
<0.00013% NaCl 26.3(9.0) 18.5(6.8) 17.0(7.5) 20.9(9.3) 20.0(8.9)***
Glucose 25.7(8.8) 16.7(5.5) 9.8(3.1) 9.3(3.4) 11.5(4.4)*
p (GLM between) < 0.0001
p (ANOVA) 0.624 <0.01 <0.0001 <0.0001 <0.0001
u-ENaCγ (ng/min)
0.9% NaCl 351.2(155.0) 302.3(108.5) 341.2(123.0) - 327.2(111.3)
<0.00013% NaCl 358.8(160.0) 375.9(173.7) 462.6(203.4) - 435.9(168.7)**
Glucose 338.3(150.0) 301.7(128.8) 335.2(185.1) - 283.7(164.4)***
p (GLM between) 0.076
u-ENaCγCR (ng/mmol)
0.9% NaCl 36.25(3.63) 32.98(3.50) 34.40(3.63) - 32.56(3.57)
<0.0013% NaCl 37.56(3.70) 43.29(3.58) 45.83(3.72) - 44.46(3.65)***
Glucose 35.33(3.62) 32.78(3.50) 31.68(3.63) - 31.71(3.57)
p (GLM between) 0.091
Values are means with SD in brackets. General linear model (GLM) with repeated measures was performed for comparison within the group and intervention as
between subjects factor. One way ANOVA was used for comparison of means between subjects when differences were found. Paired t-test was used for
comparison within treatment group at baseline and third post infusion period *p < 0.0001, **p <0.001, *** p < 0.01.




















































































Figure 2 Effects of isotonic 0.9% saline (■), hypertonic 3%
saline (♦) and isotonic glucose (●) on plasma renin (A), plasma
angiontensin II (B) and plasma aldosterone (C) concentrations.
Values are expressed as mean ± SEM. General linear model (GLM) with
repeated measures within subjects was significant for all three variables.
Paired t-test was used for comparison within treatment groups at
postinfusion 240 min vs. basal. * p < 0.0001.
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to baseline levels with no overall significant change
(Figure 2).
AVP did not change in response to 0.9% NaCl and
glucose, but increased significantly after 3% NaCl with a
maximum at 150 minutes and a steady fall during the
post infusion period (Figure 1C).
Blood pressure, pulse rate, GFR, p-Na, p-alb and p-osm
Table 4 shows the absolute values of systolic and dia-
stolic blood pressure, pulse rate, GFR, plasma sodium
and plasma albumin during the baseline period, the in-
fusion period and the post infusion period.
Systolic BP was the same after all three infusions.
There was a small difference in diastolic BP pattern dur-
ing the examination day, but the changes were very
small and might be by chance. During the examination
day pulse rate increased slightly in response to 0.9%
NaCl and 3% NaCl, while the heart rate increased to a
higher extent in response to the glucose infusion (Table 4).
The increase in pulse rate did not differ between 0.9%
saline and 3% saline, but there was a difference in the
relative increase in pulse rate between saline and glucose
infusion (p < 0.01).
GFR increased slightly, although significantly, on the
examination day. However the changes were very small
(Table 4).
P-Na increased in response to both 0.9% NaCl and 3%
NaCl with maximum after 150 minutes. In response to
glucose p-Na decreased markedly after 150 minutes to a
mean of 128.7 mmol/l (Table 4). The increase was higher
after 3% NaCl compared to 0.9% NaCl and accordingly
the changes after glucose were lower compared to saline.
P-alb decreased significantly in response to 0.9%, 3%
NaCl and glucose infusions. The decline was significantly
lower and sustained after both saline infusions compared
to glucose, which is related to an expected increase in
extracellular fluid.
P-osm increased slightly during 0.9% NaCl infusion,
but remained unchanged at the end of the examination
day. P-osm increased significantly in response to 3%
NaCl, with a maximum of 293 mosm/kg and decreased
significantly after glucose to 280 mosm/kg at 150 min.
The changes in p-osm indicated that isotonic, hypertonic
and hypotonic conditions were established (Figure 1D).
Fluid, sodium balance and body weight during the
examination days
The average fluid administered intravenous was 1749 ml
of 0.9% NaCl (SD 270), 555 ml of 3% NaCl (SD 90) and
1736 ml of glucose (SD 282). The cumulative water
input was 3674 ml (SD 270), 2480 ml (SD 90) and
3661 ml (SD 282) respectively, as participants drank an
additional 1925 ml of tap water each examination day.During the examination days the average total urine out-
put was 1858 ml (SD 246) in subjects who received 0.9%
NaCl, 984 ml (SD 202) in subjects who received 3%
NaCl and 2682 ml (SD 351) in subjects who received
glucose. The fraction of water excreted after 240 min
was 51% when 0.9% NaCl was infused, 40% when 3%
NaCl was infused and 73% when glucose was infused. The
total amount of sodium infused was 269 mmol (SD 42) of
0.9% NaCl and 285 mmol (SD 46) of 3.0% NaCl. The cu-
mulative sodium output at 240 min was 50 mmol (SD 16)
after 0.9% NaCl, 54 mmol (SD 21) after 3% NaCl and
21 mmol (SD 9) after glucose. The fraction of sodium
excreted after 240 min was 19% after both 0.9% and 3%
Table 4 Effect of 0.9% isotonic saline (0.9% NaCl), 3.0% hypertonic saline (3% NaCl) and 5% glucose (Glucose) on
51Cr-EDTA-clearance, plasma sodium, plasma albumin, systolic blood pressure (SBP), diastolic blood pressure (DBP)
and pulse rate in a randomized, placebo-controlled, crossover study of 23 healthy subjects
Periods Baseline Infusion Post infusion p (GLM-within)
0-90 min 90-150 min 150-180 min 180-210 min 210-240 min
51Cr-EDTA-clearance (ml/min/1.73 m2)
0.9% NaCl 98.1(10.1) 97.2(9.9) 100.0(12.4) 106.4(19.5) 106.1(13.3)** 0.002
3% NaCl 95.7(10.4) 93.0(11.4) 96.6(14.8) 97.0(14.8) 101.8(13.9)***
Glucose 96.9(10.3) 100.0 (9.9) 105.9(10.5) 104.0(13.9) 99.1(9.7)
p (GLM between) 0.244
p-Sodium (mmol/l)
0.9% NaCl 138.1(2.1) 139.4(2.1) 139.6(2.4) 139.1(2.4) 138.7(2.3)** <0.0001
3% NaCl 138.0(2.0) 142.5(1.8) 141.7(1.7) 141.1(2.1) 139.7(2.0)*
Glucose 138.1(2.0) 128.7(3.7) 134.1(3.6) 135.7(3.7) 136.9(2.9)*
p (GLM between) <0.0001
p (ANOVA) 0.94 <0.0001 <0.0001 <0.0001 =0.001
p-albumin (g/L)
0.9% NaCl 40.3(2.6) 40.1(2.4) 35.3(2.0) 35.8(2.1) 36.0(2.2)* <0.0001
3% NaCl 40.1(2.6) 39.8(2.6) 35.2(2.2) 36.0(2.3) 36.2(2.7)*
Glucose 40.9(2.2) 40.3(2.8) 36.1(2.5) 39.1(2.7) 39.7(2.9)*
p (GLM between) <0.05
p (ANOVA) 0.510 0.765 0.328 <0.0001 <0.0001
SBP (mmHg)
0.9% NaCl 114.5(10.6) 117.7(10.4) 116.6(11.0) 116.9(11.6) 117.7(11.5) 0.439
3% NaCl 114.0(9.5) 117.9(9.1) 117.2(9.2) 115.5(10.0) 116.4(9.7)
Glucose 115.5(8.4) 118.2(9.8) 117.7(9.1) 115.5(8.2) 117.0(9.1)
p (GLM between) 0.975
DBP (mmHg)
0.9% NaCl 62.9(4.3) 64.0(6.1) 62.2(5.7) 63.3(5.6) 63.4(5.1) 0.038
3% NaCl 62.9(4.2) 62.1(5.0) 61.0(5.4) 61.4(4.9) 62.9(4.9)
Glucose 64.4(4.2) 65.8(5.6) 65.3(6.3) 65.5(5.3) 63.6(7.5)
p (GLM between) 0.12
Pulse rate
0.9% NaCl 54.1(11.0) 57.2(11.9) 56.4(11.6) 58.0(12.1) 57.4(11.9)* <0.0001
3% NaCl 54.0(10.5) 58.2(11.2) 57.0(11.2) 56.9(11.3) 57.7(11.5)*
Glucose 54.7(10.5) 57.4(12.5) 57.1(12.0) 60.3(11.7) 61.3(12.3)*
p (GLM between) 0.917
Values are mean with SD in brackets. General linear model (GLM) with repeated measures was performed for comparison within the group and intervention as
between subjects factor. One way ANOVA was performed for comparison of means when differences were found between intervensions. Paired t-test was used
for comparison within treatment groups at baseline and post infusion period 210 – 240 minutes. *p < 0.0001; **p < 0.001; ***p < 0.05.
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increased bodyweight in response to 0.9% NaCl from
73.2 kg (SD 11.3) at baseline to 74.3 kg (SD 11.4) at the
end of the study day [+1.1 kg (SD 0.39); p < 0.0001], in
response to 3% NaCl from 73.3 kg (SD 11.6) at baseline
to 74.1 kg (SD 11.7) at the end of the study day
[+0.8 kg (SD 0.39); p < 0.0001] and to a smaller extent
in response to glucose from 72.8 kg (SD 11.8) atbaseline to 73.1 kg (SD12.0) at the end of the study day
[+0.3 kg (SD 0.5); p <0.05].
Discussions
In the present study we examined the effect of an acute
intravenous volume load of 0.9% saline, 3% saline and
isotonic glucose infusions on u-AQP2 and u-ENaCγ in a
randomized, crossover study of healthy subjects. The
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aquaporin 2 water channels and the epithelial sodium
channels in the principal cells in the distal part of the
nephron.
During infusion and in the period immediately after,
adaptive physiological changes take place in renal func-
tion and vasoactive hormones. Thus, the main changes
in the effect variables could be expected to occur after
the infusion. In the present study, we paid special atten-
tion to changes in the effect variables in the last post infu-
sion period (Post infusion 210–240), i.e. 60–90 minutes
after infusion had ceased. During this period, u-AQP2
increased after hypertonic and isotonic saline infusion
and decreased after glucose infusion. At the same time,
u-ENaCγ increased after hypertonic saline infusion and
remained unchanged after isotonic saline and glucose
infusion.
U-AQP2 after infusion with hypotonic and isotonic saline
and isotonic glucose
Aquaporin-2 (AQP2) is located in the collecting duct
principal cells [11] and is expressed in the apical plasma
membrane [12]. Vasopressin (AVP) regulates AQP2 by
binding to V2 receptors in the basolateral membrane,
[11,13]. Short term exposure to AVP causes trafficking
and insertion of the intracellular vesicles, containing
AQP2, to the apical membrane and increases the water
permeability and absorption [11-14]. Long-term regula-
tion occurs over a period of hours to days, and is caused
by AVP-regulated gene transcription resulting in an
increase in AQP2 whole-cell abundance [4,13]. Experi-
ments in rats showed that infusion of dDAVP increased
u-AQP2 [15]. This is consistent with the view that
increased delivery of AQP2 channels to the apical mem-
brane results in increased excretion of AQP2 after
stimulation with AVP [6,15-21]. Approximately 3% of
AQP2 in the collecting duct are excreted into urine [20],
but the underlying mechanisms are unknown.
Volume expansion with 3% hypertonic saline in-
creases plasma osmolarity beyond the threshold of the
hypothalamic osmoreceptors, triggering release of AVP
and a subsequent increase in u-AQP2. Saito et al found
a significant relationship between urinary excretion of
AQP2 and p-AVP in healthy subjects after 5% hyper-
tonic saline infusion [17]. Pedersen et al found a posi-
tive correlation between u-AQP2 and p-AVP during
24 h of water deprivation and after 3% hypertonic sa-
line infusion [6]. Thus, previous studies in humans
have demonstrated that the activity of the AQP2 water
channels can be determined by measuring u-AQP2
[6-8,17,18]. Surprisingly, Baumgartner et al found no
change in u-AQP2 after infusion of 2.5% NaCl in
healthy volunteers, despite a significant rise in both
urine osmolarity and AVP [22]. However, the oralwater load was 3–4 times higher prior to infusion com-
pared to our study. Thus, the large water load before
infusion might have overruled the stimulatory effects
of hypertonic saline. As expected, our study showed
that u-AQP2 increased after 3% NaCl with a corre-
sponding rise in urine osmolarity and a reduction in
CH2O. Thus, our findings indicate an increased water
reabsorption via the aquaporin-2 water channels in the
distal tubules. Prior to the increase in u-AQP2, there
was an abrupt rise in p-osm and p-AVP induced by the
hypertonic saline infusion. Animal studies have shown
that hypertonicity can cause an up regulation of AQP2
expression in the apical membrane comparable with that
achieved by AVP alone [23,24]. It cannot be excluded that
this might play an active part in the increased excretion of
u-AQP2. Most likely, the increased water reabsorption
was mediated by an increase in p-AVP. U-AQP2 contin-
ued to rise throughout the examination day, suggesting
that AQP2 channels remained inserted and active in the
apical membrane due to actions of elevated p-AVP.
Infusion of isotonic saline depresses the fractional
water and salt reabsorption in the proximal tubules in
animals [25]. In the present study, infusion with 0.9%
NaCl caused the same response in u-AQP2, u-osm and
CH2O as 3% NaCl infusion, albeit to a lesser extent.
There was a small rise in p-osm to a maximum level of
286 mosmol/kg corresponding to a rise of 0.5%. This
increase is below the osmoreceptor threshold, and we
did not see, nor expect, any significant change in p-AVP.
Therefore AVP could not be the main regulator of
AQP2 during 0.9% NaCl. Most likely, the increased water
transport via AQP2 is a compensatory phenomenon to
antagonize a decrease in the renal water absorption in the
proximal tubules, which occurs after isotonic volume
expansion. The mechanism might be due to an increased
activity in the natriuretic peptide system [26,27].
Infusion of 5% glucose causes a volume expansion dis-
tributed throughout the fluid phases in the body with only
a very small increase in plasma volume. This is illustrated
in the measurements of plasma albumin, where concentra-
tions at 240 min were virtually equal to baseline (Table 4),
indicating no change in extracellular fluid. According to
our knowledge, no study has measured u-AQP2 after glu-
cose infusion. A study of healthy subjects showed, that after
an oral water load of 20 mL/kg for 15 minutes (mean in-
take 1605 ml) u-AQP2 decreased 17% after 210 minutes
[21]. In a recent study, subjects received an oral water load
of 20 ml/kg for 15 min (mean intake 1389 ml) with a subse-
quent 27% decrease in u-AQP2 after 240 minutes [28].
Both plasma osmolarity and p-AVP decreased. Thus, it has
been showed that u-AQP2 is reduced during water diuresis
after oral water intake [21,28,29].
In our study, subjects received a mean of 1736 ml
glucose IV. In the last post infusion period the expected
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u-AQP2cr, a decrease in u-osm and an increase in UO and
CH2O. Plasma osmolarity decreased from 285 mosm/kg to
280 m0sm/kg, i.e. a 2% decline, but with no accompanying
reduction in p-AVP. Our findings indicate a reduced
reabsorption of water via the aquaporin-2 water channels
in the distal tubules after isotonic glucose infusion. The
lack of change in p-AVP could firstly be explained by the
fact that the subjects had received 1225 ml of oral water
load prior to the infusion start, and this could have
suppressed AVP in baseline periods beforehand. Secondly,
the measurements of p-AVP concentration may not be
sensitive enough to detect a small decrease. The recent
discovered peptide Apelin, may also play a role. Apelin is
colozalized with AVP in magnocellular neurons of hypo-
thalamus [30,31]. In healthy male volunteers decreasing
plasma osmolarity by waterloading reduced p-AVP mod-
estly but p-Apelin increased rapidly [32]. Apelin regulation
is opposite to that of AVP and data suggests that Apelin,
like AVP may participate in regulating water homeostasis
[32]. We did not measure p-Apelin, but it could have
been of interest to investigate plasma apelin in parallel
with p-AVP in conditions of different volume expansions.
Thus, in the last post-infusion period, u-AQP2 increased
approximately to the same extent after hypertonic and iso-
tonic saline infusions, whereas a marked fall was seen after
isotonic glucose infusion. A possible explanation for the
delay in changes of u-AQP2 could be that it takes few
minutes for changes in AVP to act on the principal cell,
either by insertion or removal of AQP2 from the apical
membrane, but it takes several minutes before the effect is
seen in the excretion of u-AQP2 in the urine.
U-ENaCγ after infusion with hypotonic and isotonic saline
and isotonic glucose
Sodium transport across the collecting duct occurs
through the epithelial sodium channel and is responsible
for reabsorption of 3–5 % of filtered sodium [33]. ENaC is
composed of three distinct subunits: α, β and γ and local-
ized at the apical plasma membrane of principal cells
[34,35]. ENaC is a target of aldosterone that acts on the
mineralocorticoid receptor. Aldosterone increases sodium
transport by redistributing ENaC subunits from intracellu-
lar locations to the apical membrane as well as altering
gene transcription [33,36,37]. While the action of aldoster-
one occurs over hours or days, another synergistically
pathway involves AVP [35,37-41]. In the cortical collecting
ducts in rats, AVP binds to the V2 receptors, stimulates
cAMP and increases sodium reabsorption by promoting
trafficking and insertion of ENaC into the apical mem-
brane inducing a rapid change in channel activity
[34,35,40]. Recent studies in humans demonstrated
that AVP, via V2 receptors, stimulates ENaC mediated
sodium reabsorption across principal cells [39,42,43].Fractions of ENaC are normally excreted into the urine.
The amount of ENaC-fractions is supposed to reflect the
activity of the sodium transport via the epithelial sodium
channels just as u-AQP2 reflects the functional status of
the AQP2 water channels. Recently, our group introduced
a new method to evaluate sodium reabsorption in the
principal cells in the distal tubules. Lauridsen et al demon-
strated a significant correlation between changes in urin-
ary sodium excretion and changes in urinary excretion of
the beta fraction (u-ENaCβ) in healthy humans [44,45].
Apparently, u-ENaCβ can be used as a biomarker for
the transport of sodium via ENaC. In the present study,
we measured the gamma fraction of the protein of the
epithelial sodium channels to evaluate the up-and down
regulation of γ-ENaC expression and sodium transport
via ENaC as previously reported from our group [9,46].
The sodium-chloride symporter (NCC) in the distal
convoluted tubules (DCT) is as another major sodium
reabsorbing pathway. Sodium reabsorption in DCT is es-
sential to define the amount of sodium delivery to the
principal cells in the collecting duct. It is widely accepted
that NCC is regulated by Ang II and aldosterone [47,48].
Studies have also shown that high AVP increase phosphor-
ylation of NCC and presumably result in greater sodium
reabsorption [49].
Experimental animal-studies have demonstrated that
isotonic and hypertonic saline IV reduced reabsorption of
sodium in the proximal tubules, and thereby increased the
amount of sodium in the urine [25,50]. Andersen LJ et al
studied the effects of hypertonic and isotonic saline in
healthy subjects on a controlled diet. The subjects received
an IV sodium load of either 25 ml/kg isotonic saline or
4.5 ml/kg 3% hypertonic saline for 90 minutes [51]. Urinary
sodium excretion increased in both isotonic and hypertonic
saline, with natriuresis after hypertonic saline exceeding
that after isotonic saline. Plasma sodium and plasma osmo-
larity increased substantially after hypertonic saline, as did
p-AVP. Our study showed that 3% NaCl infusion increased
u-ENaCγ, FENa, p-Osm, p-Na and p-AVP. Thus, our find-
ings reflect an increased sodium reabsorption via ENaC in
the principal cells, and furthermore confirmed the results
by Andersen et al [51]. The increased u-ENaCγ could
partly be explained by a considerable decrease in the renal
sodium absorption proximal in the nephron, compensated
for and adjusted by an increase in absorption in the distal
part. However, the rise in p-AVP seen immediately after
3% NaCl infusion could also indicate that the increased
u-ENaCγ is caused by actions of AVP. An increased
sodium movement from the lumen to the cell via ENaC
would theoretically drive potassium secretion through
the ROMK channels [52,53]. Surprisingly we measured
a fall in excretion of potassium in the urine. This could
argue against a major role of ENaC mediated sodium
transport. If NCC increased sodium reabsorption, both
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and due to high p-AVP, then less sodium would to be
transported by ENaC and thus potassium secretion
would not take place. A possible role of NCC after infu-
sion with hypertonic saline is purely speculative as we
did not measure the activity of NCC. Perhaps we did
not see the positive effect on potassium secretion within
our time limits. However, the potassium transport is
complex and factors modulating potassium transport,
such as altered tubular flow and aldosteron, are many.
After volume expansion with isotonic saline the oncotic
pressure is slightly reduced, which leads to an immediately
increase in GFR and smaller reabsorption of water in
the proximal tubule. We measured a small increase in
GFR and UO output. Sodium excretion increased, but
u-ENaCγ, p-Na, p-osm and p-AVP remained unchanged,
thus the findings were as we expected. Regarding NCC,
one would not expect any change in NCC mediated
sodium reabsorption during isotonic saline.
No study has ever evaluated u-ENaCγ during water di-
uresis. In our study, we measured a trend towards a reduc-
tion in u-ENaCγ after glucose infusion reflecting a small
reduction of sodium reabsorption via ENaC in the princi-
pal cell. As previously mentioned, we measured a 2% fall
in p-osmolality after glucose infusion, which theoretically
should trigger a decrease in AVP. We did not detect a fall
in p-AVP, presumably due to a low p-AVP caused by oral
water loading in advance or the fact that the measure-
ments of p-AVP concentration may not be sensitive
enough to detect small changes. It could be hypothesized
that the decrease in u-ENaCγ could be due to a lack of
AVP binding to V2 receptors in the basolateral membrane
of the principal cell. Lack of AVP stimuli leads to an in-
creased endocytosis of ENaC channels from the mem-
brane surface into recycling vesicles, there by decreasing
reabsorption of sodium [54,55].
Thus, in the last post infusion period u-ENaCγ in-
creased markedly after hypertonic saline infusion, was
approximately at the same level after isotonic saline and
decreased or tended to decrease in response to glucose
infusion. The rise in p-osm and p-AVP was seen imme-
diately after 3% NaCl infusion stopped. The delay and
constant level of u-ENaCγ after hypertonic saline could
be explained by the fact that it takes few minutes to in-
crease trafficking of intracellular depots of ENaC channels
into the apical membrane but several minutes to excrete
ENaC into the urine after stimulation with AVP.
Vasoactive hormones
In addition to AVP, the renin-angiotensin-aldosterone
system (RAAS) is a key regulator of renal sodium excre-
tion and thereby of body fluid volume. It is well known
that sodium depletion activates and that chronic sodium
load reduces the RAAS [56]. In vitro and in vivo studieshave shown that aldosterone stimulates the mineralocor-
ticoid receptor to an increased transcription of genes-
encoding proteins involved in sodium transport i.e. ENaC
and Na,K-ATPase [57].
Numerous studies of changes in blood volume have
demonstrated that acute changes are associated with
inverse adjustments of the renin-angiotensin-aldosterone
system [21,27,51,58]. In the present study, volume ex-
pansion with 3% and 0.9% saline resulted in a similar
and significant reduction in PRC, p-AngII and Aldo
consistent with an increase in extracellular volume. This
is in agreement with previous studies [51,58].
After glucose infusion, we measured no significant
change in PRC, p-AngII or p-Aldo. This was expected,
as glucose infusion does not cause any marked change
in extracellular volume. Our study was not designed to
allow any regulatory effects of aldosterone as the action
of aldosterone occurs over hours or days. Therefor other
factors must be implicated in the regulation of ENaC.Strengths and limitations
The major strength of this study was the design as a ran-
domized crossover study with a homogenous group of
healthy young men and women. The test conditions were
very well defined regarding diet, sodium and fluid intake.
Thus, the results are not confounded by different salt or
water balance. This study explored only the acute effects
of volume expansion. No doubt, we could have gained
further information regarding the long-term effects of
volume expansion and the urinary excretion of AQP2 and
ENaCγ if the post infusion period had been longer. In
addition, the study was not placebo-controlled, by means
of infusion with a negligible amount of 0.9% saline. This
could have distinguished the effects of volume expansion
from the overall variability of water and salt reabsorption.
In this study it was not possible to perform ANP measure-
ments. It could have made a positive contribution to our
results.Conclusions
In conclusion volume expansion with 3% and 0.9% saline
clearly increased u-AQP2, while isotonic glucose de-
creased u-AQP2. Infusion of hypertonic saline increased
u-ENaCγ, whereas u-ENaCγ was not significantly
changed after isotonic saline and decreased or tended to
decrease after glucose. Thus, the transport of water and
sodium changed, both via the aquaporin 2 water chan-
nels and the epithelial sodium channels, during all three
types of volume expansion in order to regulate and
maintain water- and sodium homeostasis in the body.
Changes in the renin-angiotensin-aldosterone system did
not seem to bear a causal relationship with the changes
in u-AQP2 or u-ENaCγ.
Jensen et al. BMC Nephrology 2013, 14:202 Page 13 of 14
http://www.biomedcentral.com/1471-2369/14/202Competing interests
The authors declare that they have no competing interests. The authors
alone are responsible for the content and writing of the paper.
Authors’ contributions
All authors have contributed to the manuscript. JMJ, FHM and EBP designed
the project. JMJ and FHM performed the experiments and statistical
analyzes. JMJ, FHM, JNB, SN and EBP wrote and edited the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
The authors greatly acknowledge the skilful assistance of our laboratory
technicians: Lisbeth Mikkelsen, Anne Mette Ravn, Kirsten Nygaard and
Henriette Vorup Simonsen.
Funding
The study was supported by grants from Region Midt’s Research Foundation
for Health Science, The Lundbeck Foundation and Helen and Ejnar Bjornows
Foundation.
Author details
1Department of Medical Research, Holstebro Hospital, Laegaardvej 12,
Holstebro 7500, Denmark. 2Aarhus University, Aarhus, Denmark. 3Water and
Salt Research Centre, Aarhus University, Aarhus, Denmark.
Received: 20 June 2013 Accepted: 23 September 2013
Published: 26 September 2013
References
1. Rossier BC, Canessa CM, Schild L, Horisberger JD: Epithelial sodium
channels. Curr Opin Nephrol Hypertens 1994, 3(5):487–496.
2. Buemi M, Nostro L, Di Pasquale G, Cavallaro E, Sturiale A, Floccari F, Aloisi C,
Ruello A, Calapai G, Corica F, Frisina N: Aquaporin-2 water channels in
spontaneously hypertensive rats. Am J Hypertens 2004, 17(12 Pt 1):1170–1178.
3. Su YR, Menon AG: Epithelial sodium channels and hypertension. Drug
Metab Dispos 2001, 29(4 Pt 2):553–556.
4. Nielsen S, Kwon TH, Frokiaer J, Knepper MA: Key roles of renal aquaporins
in water balance and water-balance disorders. News Physiol Sci 2000,
15:136–143.
5. Rossier BC, Pradervand S, Schild L, Hummler E: Epithelial sodium channel
and the control of sodium balance: interaction between genetic and
environmental factors. Annu Rev Physiol 2002, 64:877–897.
6. Pedersen RS, Bentzen H, Bech JN, Pedersen EB: Effect of water deprivation
and hypertonic saline infusion on urinary AQP2 excretion in healthy
humans. Am J Physiol Renal Physiol 2001, 280(5):F860–7.
7. Graffe CC, Bech JN, Pedersen EB: Effect of high and low sodium intake on
urinary aquaporin-2 excretion in healthy humans. Am J Physiol Renal
Physiol 2012, 302(2):F264–75.
8. Lauridsen TG, Vase H, Starklint J, Bech JN, Pedersen EB: Protein-enriched
diet increases water absorption via the aquaporin-2 water channels in
healthy humans. Nephrol Dial Transplant 2010, 25(8):2502–2510.
9. Matthesen SK, Larsen T, Vase H, Lauridsen TG, Jensen JM, Pedersen EB:
Effect of amiloride and spironolactone on renal tubular function and
central blood pressure in patients with arterial hypertension during
baseline conditions and after furosemide: a double-blinded, randomized,
placebo-controlled crossover trial. Clin Exp Hypertens 2012, 35(5):313.
10. Hager H, Kwon TH, Vinnikova AK, Masilamani S, Brooks HL, Frokiaer J,
Knepper MA, Nielsen S: Immunocytochemical and immunoelectron
microscopic localization of alpha-, beta-, and gamma-ENaC in rat kidney.
Am J Physiol Renal Physiol 2001, 280(6):F1093–106.
11. Kwon TH, Hager H, Nejsum LN, Andersen ML, Frokiaer J, Nielsen S:
Physiology and pathophysiology of renal aquaporins. Semin Nephrol
2001, 21(3):231–238.
12. Nielsen S: Renal aquaporins: an overview. BJU Int 2002, 90(Suppl 3):1–6.
13. DiGiovanni SR, Nielsen S, Christensen EI, Knepper MA: Regulation of
collecting duct water channel expression by vasopressin in Brattleboro
rat. Proc Natl Acad Sci U S A 1994, 91(19):8984–8988.
14. Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, Knepper MA:
Vasopressin increases water permeability of kidney collecting duct by
inducing translocation of aquaporin-CD water channels to plasma
membrane. Proc Natl Acad Sci U S A 1995, 92(4):1013–1017.15. Wen H, Frokiaer J, Kwon TH, Nielsen S: Urinary excretion of aquaporin-2 in
rat is mediated by a vasopressin-dependent apical pathway. J Am Soc
Nephrol 1999, 10(7):1416–1429.
16. Kanno K, Sasaki S, Hirata Y, Ishikawa S, Fushimi K, Nakanishi S, Bichet DG,
Marumo F: Urinary excretion of aquaporin-2 in patients with diabetes
insipidus. N Engl J Med 1995, 332(23):1540–1545.
17. Saito T, Ishikawa SE, Sasaki S, Nakamura T, Rokkaku K, Kawakami A, Honda K,
Marumo F, Saito T: Urinary excretion of aquaporin-2 in the diagnosis of
central diabetes insipidus. J Clin Endocrinol Metab 1997, 82(6):1823–1827.
18. Elliot S, Goldsmith P, Knepper M, Haughey M, Olson B: Urinary excretion of
aquaporin-2 in humans: a potential marker of collecting duct
responsiveness to vasopressin. J Am Soc Nephrol 1996, 7(3):403–409.
19. Pisitkun T, Shen RF, Knepper MA: Identification and proteomic profiling of
exosomes in human urine. Proc Natl Acad Sci U S A 2004, 101(36):13368–13373.
20. Rai T, Sekine K, Kanno K, Hata K, Miura M, Mizushima A, Marumo F, Sasaki S:
Urinary excretion of aquaporin-2 water channel protein in human and
rat. J Am Soc Nephrol 1997, 8(9):1357–1362.
21. Pedersen RS, Bentzen H, Bech JN, Nyvad O, Pedersen EB: Urinary
aquaporin-2 in healthy humans and patients with liver cirrhosis and
chronic heart failure during baseline conditions and after acute water
load. Kidney Int 2003, 63(4):1417–1425.
22. Baumgarten R, van de Pol MH, Deen PM, van Os CH, Wetzels JF: Dissociation
between urine osmolality and urinary excretion of aquaporin-2 in healthy
volunteers. Nephrol Dial Transplant 2000, 15(8):1155–1161.
23. Hasler U, Nunes P, Bouley R, Lu HA, Matsuzaki T, Brown D: Acute
hypertonicity alters aquaporin-2 trafficking and induces a MAPK-
dependent accumulation at the plasma membrane of renal epithelial
cells. J Biol Chem 2008, 283(39):26643–26661.
24. Marples D, Christensen BM, Frokiaer J, Knepper MA, Nielsen S: Dehydration
reverses vasopressin antagonist-induced diuresis and aquaporin-2
downregulation in rats. Am J Physiol 1998, 275(3 Pt 2):F400–9.
25. DIRKS JH, CIRKSENA WJ, BERLINER RW: The effects of saline infusion on
sodium reabsorption by the proximal tubule of the Dog. J Clin Invest
1965, 44:1160–1170.
26. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H: A rapid and potent
natriuretic response to intravenous injection of atrial myocardial extract
in rats. Life Sci 1981, 28(1):89–94.
27. Singer DR, Shore AC, Markandu ND, Buckley MG, Sagnella GA, MacGregor
GA: Dissociation between plasma atrial natriuretic peptide levels and
urinary sodium excretion after intravenous saline infusion in normal
man. Clin Sci (Lond) 1987, 73(3):285–289.
28. Pedersen EB, Thomsen IM, Lauridsen TG: Abnormal function of the
vasopressin-cyclic-AMP-aquaporin2 axis during urine concentrating and
diluting in patients with reduced renal function. A case control study.
BMC Nephrol 2010, 11:26.
29. Saito T, Higashiyama M, Nakamura T, Kusaka I, Nagasaka S, Saito T, Ishikawa
S: Urinary excretion of the aquaporin-2 water channel exaggerated in
pathological states of impaired water excretion. Clin Endocrinol (Oxf )
2001, 55(2):217–221.
30. Reaux A, De Mota N, Skultetyova I, Lenkei Z, El Messari S, Gallatz K, Corvol P,
Palkovits M, Llorens-Cortes C: Physiological role of a novel neuropeptide,
apelin, and its receptor in the rat brain. J Neurochem 2001,
77(4):1085–1096.
31. De Mota N, Reaux-Le Goazigo A, El Messari S, Chartrel N, Roesch D, Dujardin
C, Kordon C, Vaudry H, Moos F, Llorens-Cortes C: Apelin, a potent diuretic
neuropeptide counteracting vasopressin actions through inhibition of
vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci
U S A 2004, 101(28):10464–10469.
32. Azizi M, Iturrioz X, Blanchard A, Peyrard S, De Mota N, Chartrel N, Vaudry H,
Corvol P, Llorens-Cortes C: Reciprocal regulation of plasma apelin and
vasopressin by osmotic stimuli. J Am Soc Nephrol 2008, 19(5):1015–1024.
33. Edinger RS, Bertrand CA, Rondandino C, Apodaca GA, Johnson JP, Butterworth
MB: The epithelial sodium channel (ENaC) establishes a trafficking vesicle
pool responsible for its regulation. PLoS One 2012, 7(9):e46593.
34. Ecelbarger CA, Kim GH, Terris J, Masilamani S, Mitchell C, Reyes I, Verbalis JG,
Knepper MA: Vasopressin-mediated regulation of epithelial sodium channel
abundance in rat kidney. Am J Physiol Renal Physiol 2000, 279(1):F46–53.
35. Schild L: The epithelial sodium channel and the control of sodium
balance. Biochim Biophys Acta 2010, 1802(12):1159–1165.
36. Butterworth MB: Regulation of the epithelial sodium channel (ENaC) by
membrane trafficking. Biochim Biophys Acta 2010, 1802(12):1166–1177.
Jensen et al. BMC Nephrology 2013, 14:202 Page 14 of 14
http://www.biomedcentral.com/1471-2369/14/20237. Garty H, Palmer L: Epithelial sodium channels: function, structure and
regulation. Physiol Rev 1997, 77(2):359–396.
38. Andersen LJ, Andersen JL, Schutten HJ, Warberg J, Bie P: Antidiuretic effect
of subnormal levels of arginine vasopressin in normal humans.
Am J Physiol 1990, 259(1 Pt 2):R53–60.
39. Bankir L, Fernandes S, Bardoux P, Bouby N, Bichet DG: Vasopressin-V2
receptor stimulation reduces sodium excretion in healthy humans.
J Am Soc Nephrol 2005, 16(7):1920–1928.
40. Ecelbarger CA, Kim GH, Wade JB, Knepper MA: Regulation of the
abundance of renal sodium transporters and channels by vasopressin.
Exp Neurol 2001, 171(2):227–234.
41. Bugaj V, Pochynyuk O, Stockand JD: Activation of the epithelial Na +
channel in the collecting duct by vasopressin contributes to water
reabsorption. Am J Physiol Renal Physiol 2009, 297(5):F1411–8.
42. Perucca J, Bichet DG, Bardoux P, Bouby N, Bankir L: Sodium excretion in
response to vasopressin and selective vasopressin receptor antagonists.
J Am Soc Nephrol 2008, 19(9):1721–1731.
43. Stockand JD: Vasopressin regulation of renal sodium excretion. Kidney Int
2010, 78(9):849–856.
44. Lauridsen TG, Vase H, Bech JN, Nielsen S, Pedersen EB: Direct effect of
methylprednisolone on renal sodium and water transport via the
principal cells in the kidney. Eur J Endocrinol 2010, 162(5):961–969.
45. Lauridsen TG, Vase H, Starklint J, Graffe CC, Bech JN, Nielsen S, Pedersen EB:
Increased renal sodium absorption by inhibition of prostaglandin
synthesis during fasting in healthy man. A possible role of the epithelial
sodium channels. BMC Nephrol 2010, 11:28.
46. Matthesen SK, Larsen T, Vase H, Lauridsen TG, Pedersen EB: Effect of
potassium supplementation on renal tubular function, ambulatory blood
pressure and pulse wave velocity in healthy humans. Scand J Clin Lab
Invest 2012, 72(1):78–86.
47. Kim GH, Masilamani S, Turner R, Mitchell C, Wade JB, Knepper MA: The
thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein.
Proc Natl Acad Sci U S A 1998, 95(24):14552–14557.
48. Sandberg MB, Riquier AD, Pihakaski-Maunsbach K, McDonough AA,
Maunsbach AB: ANG II provokes acute trafficking of distal tubule
Na + −Cl(−) cotransporter to apical membrane. Am J Physiol Renal Physiol
2007, 293(3):F662–9.
49. Pedersen NB, Hofmeister MV, Rosenbaek LL, Nielsen J, Fenton RA:
Vasopressin induces phosphorylation of the thiazide-sensitive sodium
chloride cotransporter in the distal convoluted tubule. Kidney Int 2010,
78(2):160–169.
50. Svensen CH, Waldrop KS, Edsberg L, Hahn RG: Natriuresis and the extracellular
volume expansion by hypertonic saline. J Surg Res 2003, 113(1):6–12.
51. Andersen LJ, Andersen JL, Pump B, Bie P: Natriuresis induced by mild
hypernatremia in humans. Am J Physiol Regul Integr Comp Physiol 2002,
282(6):R1754–61.
52. Castaneda-Bueno M, Arroyo JP, Gamba G: Independent regulation of Na +
and K + balance by the kidney. Med Princ Pract 2012, 21(2):101–114.
53. Giebisch GH: A trail of research on potassium. Kidney Int 2002,
62(5):1498–1512.
54. Butterworth MB, Edinger RS, Frizzell RA, Johnson JP: Regulation of the
epithelial sodium channel by membrane trafficking. Am J Physiol Renal
Physiol 2009, 296(1):F10–24.
55. Butterworth MB, Edinger RS, Johnson JP, Frizzell RA: Acute ENaC
stimulation by cAMP in a kidney cell line is mediated by exocytic
insertion from a recycling channel pool. J Gen Physiol 2005, 125(1):81–101.
56. Damkjaer M, Isaksson GL, Stubbe J, Jensen BL, Assersen K, Bie P: Renal renin
secretion as regulator of body fluid homeostasis. Pflugers Arch 2012, 465(1):153.
57. Loffing J, Korbmacher C: Regulated sodium transport in the renal
connecting tubule (CNT) via the epithelial sodium channel (ENaC).
Pflugers Arch 2009, 458(1):111–135.
58. Andersen LJ, Jensen TU, Bestle MH, Bie P: Isotonic and hypertonic sodium
loading in supine humans. Acta Physiol Scand 1999, 166(1):23–30.
doi:10.1186/1471-2369-14-202
Cite this article as: Jensen et al.: Effect of volume expansion with
hypertonic- and isotonic saline and isotonic glucose on sodium and
water transport in the principal cells in the kidney. BMC Nephrology
2013 14:202.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
